Inloggen

Login
 
Wachtwoord vergeten?

Biocartis forum geopend

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
3.172 Posts
Pagina: «« 1 ... 89 90 91 92 93 ... 159 »» | Laatste | Omlaag ↓
  1. forum rang 4 MisterBlues 30 januari 2020 12:48
    quote:

    Flatlander schreef op 29 januari 2020 23:52:


    MB

    Good overview. The areas where timely MDx data may be applied are vary vast indeed. The landscape is evolving quickly. As Hans90 pointed out on 1-27-20, a few of the other companies he follows (i.e., Quanterix, Luminex and Nanostring) are offering products that specifically target pharma companies that are active some of the areas you discuss.

    I think you are missing Pharmacogenetic testing (PGx). I'm somewhat optimistic of Idylla's potential in PGx. Essentially this would be a MDx test that looks for a specific gene or lack of a gene that might influence how a specific pharma product is metabolized. Some people have mutations that either make them hyper sensitive or the reverse (they need much higher dosage to get the same effect). Because this type of am assay would most likely be run at the POC with quick results being desirable, it would seem like a Ideal fit (Haha). If the assay can be run at the doctors office with results available by the time the patient sees the pharmacist it could be very valuable.

    The attached link discusses this further.

    FL



    www.ncbi.nlm.nih.gov/pmc/articles/PMC...


    FL, Nice lead & link. Back in march 5, 2020 MB
  2. forum rang 4 MisterBlues 30 januari 2020 12:58
    quote:

    Flatlander schreef op 30 januari 2020 00:41:


    MB

    Your point about the business model is well taken. Up until this point we have primarily been discussing console sales and proprietary cartridge content. The business model will change when we have to start figuring partner content cartridges (OncoType Dx, Septicyte, etc.) where BCART gets reimbursed for its manufacturing costs and receives a royalty based on the content providers sales, profits etc. The fact of the matter is we do not know the specific terms for any of these partnerships. One thing that usually occurs, is that the early partners get better terms than the later ones once Idylla becomes better established.

    My chief concern in these types of partnerships is that the development time seems to be eclipsing my previous estimate of 2 years, where it now appears to be 3 years or more from the time of the announcement of a partnership until the time that EU marking is achieved. Since the systems may be deployed for decades, this is probably tolerable. However, length development time could become an impediment to new partnerships. I realize a lot of technology is necessary for each assay. However, a major focus must remain expediting the R&D product cycle process.

    FL




    It is not that important to know it exactly. I can make calculations taking minimumprofit margins to reach break-even considering cashposition and cashburn. Back in March 2020. (We can talk a lot, most important still is FDA and EMA approvals for assay's of BCART's making.)
  3. Kiadis-Kenner 30 januari 2020 13:04
    quote:

    MisterBlues schreef op 30 januari 2020 12:58:


    [...]

    It is not that important to know it exactly. I can make calculations taking minimumprofit margins to reach break-even considering cashposition and cashburn. Back in March 2020. (We can talk a lot, most important still is FDA and EMA approvals for assay's of BCART's making.)


    Hi MB,

    Any idea when we can expect a filing? Or did this already happen? What dates do we need to look upon?

    Many thanks
  4. euroke 30 januari 2020 13:11
    quote:

    nat1966 schreef op 30 januari 2020 12:58:


    zal zeker gelijk krijgen XiXiX , niet aan twijfelen ,de hete soep is helemaal op
    tenzij je koude soep lust dan moet je maar kopen en kopen


    Tegen paniekaanvallen bestaat al medicatie hoor! :-)

    Er gebeurt niks extra negatief bij Biocartis dan normaal mee zakken met de "Corona-paniek".
3.172 Posts
Pagina: «« 1 ... 89 90 91 92 93 ... 159 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Biocartis Meer »

Koers 4,420   Verschil -0,03 (-0,67%)
Laag 4,400   Volume 77.864
Hoog 4,495   Gem. Volume 209.873
3 jul 2020 17:35
label premium

Biocartis herpakt zich

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare